PDS Biotechnology (PDSB) Competitors $1.64 -0.03 (-1.80%) (As of 01:00 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends PDSB vs. AMLX, LFCR, ITOS, FHTX, ELDN, URGN, RZLT, AVIR, CMRX, and ATYRShould you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Amylyx Pharmaceuticals (AMLX), Lifecore Biomedical (LFCR), iTeos Therapeutics (ITOS), Foghorn Therapeutics (FHTX), Eledon Pharmaceuticals (ELDN), UroGen Pharma (URGN), Rezolute (RZLT), Atea Pharmaceuticals (AVIR), Chimerix (CMRX), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. PDS Biotechnology vs. Amylyx Pharmaceuticals Lifecore Biomedical iTeos Therapeutics Foghorn Therapeutics Eledon Pharmaceuticals UroGen Pharma Rezolute Atea Pharmaceuticals Chimerix Atyr PHARMA Amylyx Pharmaceuticals (NASDAQ:AMLX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations. Does the media refer more to AMLX or PDSB? In the previous week, Amylyx Pharmaceuticals had 3 more articles in the media than PDS Biotechnology. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 3 mentions for PDS Biotechnology. Amylyx Pharmaceuticals' average media sentiment score of 1.09 beat PDS Biotechnology's score of 0.15 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PDS Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in AMLX or PDSB? PDS Biotechnology received 38 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 69.61% of users gave PDS Biotechnology an outperform vote while only 66.00% of users gave Amylyx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmylyx PharmaceuticalsOutperform Votes3366.00% Underperform Votes1734.00% PDS BiotechnologyOutperform Votes7169.61% Underperform Votes3130.39% Is AMLX or PDSB more profitable? PDS Biotechnology has a net margin of 0.00% compared to Amylyx Pharmaceuticals' net margin of -17.86%. Amylyx Pharmaceuticals' return on equity of -36.97% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals-17.86% -36.97% -29.61% PDS Biotechnology N/A -139.57%-67.22% Do analysts prefer AMLX or PDSB? Amylyx Pharmaceuticals presently has a consensus target price of $7.33, indicating a potential upside of 80.18%. PDS Biotechnology has a consensus target price of $11.67, indicating a potential upside of 598.60%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.56PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals & insiders have more ownership in AMLX or PDSB? 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 9.5% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better valuation and earnings, AMLX or PDSB? Amylyx Pharmaceuticals has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$196.49M1.42$49.27M-$3.82-1.07PDS BiotechnologyN/AN/A-$42.94M-$1.16-1.44 Which has more volatility & risk, AMLX or PDSB? Amylyx Pharmaceuticals has a beta of -0.68, meaning that its stock price is 168% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. SummaryAmylyx Pharmaceuticals beats PDS Biotechnology on 9 of the 16 factors compared between the two stocks. Ad Prosper Trading AcademyA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading system finds high-probability option trades in less than 60 seconds a dayClick HERE to access this powerful AI Trading System Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDSB vs. The Competition Export to ExcelMetricPDS BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.47M$6.69B$5.20B$9.14BDividend YieldN/A3.00%5.12%4.29%P/E Ratio-1.4410.5287.0717.11Price / SalesN/A193.541,159.67122.74Price / CashN/A57.1643.2337.85Price / Book1.995.134.804.78Net Income-$42.94M$151.58M$120.46M$225.43M7 Day Performance-14.80%-1.40%-0.91%-0.82%1 Month Performance-20.10%-3.68%14.91%1.02%1 Year Performance-68.67%9.07%29.59%15.72% PDS Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDSBPDS Biotechnology1.1635 of 5 stars$1.64-1.8%$11.67+611.4%-68.7%$61.35MN/A-1.4120AMLXAmylyx Pharmaceuticals4.3523 of 5 stars$4.18+1.5%$7.33+75.4%-71.9%$286.53M$196.49M-1.08200Positive NewsLFCRLifecore Biomedical2.9432 of 5 stars$7.72+1.4%$10.00+29.5%+11.2%$284.30M$128.44M97.50690ITOSiTeos Therapeutics3.4831 of 5 stars$7.74+0.8%$25.25+226.2%-32.6%$282.77M$35M-2.4490FHTXFoghorn Therapeutics2.689 of 5 stars$5.02-5.3%$16.00+218.7%-26.6%$279.08M$25.52M-2.63120High Trading VolumeELDNEledon Pharmaceuticals2.1274 of 5 stars$4.51+3.0%$16.00+254.8%+173.9%$269.43MN/A-2.3310Positive NewsHigh Trading VolumeURGNUroGen Pharma3.9013 of 5 stars$11.38+0.3%$43.70+284.0%-26.1%$266.86M$82.71M-3.60200RZLTRezolute3.2015 of 5 stars$4.60+0.2%$24.13+424.5%+393.3%$266.54MN/A-3.6140Positive NewsGap UpAVIRAtea Pharmaceuticals2.9441 of 5 stars$3.14+7.2%$6.88+119.1%+2.9%$265.21M$351.37M-1.5370High Trading VolumeCMRXChimerix4.0849 of 5 stars$2.88-2.4%$8.50+195.1%+224.3%$259.03M$320,000.00-3.1472ATYRAtyr PHARMA2.5303 of 5 stars$3.08+0.7%$19.25+525.0%N/A$258.54M$235,000.00-3.2656 Related Companies and Tools Related Companies AMLX Competitors LFCR Competitors ITOS Competitors FHTX Competitors ELDN Competitors URGN Competitors RZLT Competitors AVIR Competitors CMRX Competitors ATYR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PDSB) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
